Minhua Chu: Novel Claudin18.2-Targeting ADC Drug for Pancreatic Cancer
Minhua Chu, Managing Partner at TransitionValue Partner, shared a post on X:
“Innovent Biologics has registered a Phase III clinical trial for its novel Claudin18.2-targeting ADC drug, IBI343, for the treatment of pancreatic cancer.
The trial, titled G-HOPE-002, plans to enroll 201 patients with advanced pancreatic cancer. IBI343 features a differentiated design. The ADC technology originates from a collaboration with Synaffix and utilizes glycan-mediated site-specific conjugation, with a drug-to-antibody ratio (DAR) of 4. It employs a highly internalizing antibody and incorporates Fc silencing mutations.
In July, Innovent officially disclosed the molecular structure of IBI343 (Arcotatug tavatecan).
The Ph1 results of Innovent’s anti-CLDN18.2 ADC, IBI343, in the treatment of advanced G/GEJ AC are published in Nature Medicine.
Based on these data, IBI343 has initiated an international multicenter Phase 3 clinical study (G-HOPE-001, NCT06238843) in 2024.”
Title: A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Authors: Innovent Biologics (Suzhou) Co. Ltd.
Title: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
Authors: Jia Liu, Jianwei Yang, Yuping Sun, Jifang Gong, Jinbo Yue, Yueyin Pan, Meili Sun, Rongfeng Song, Xiuying Xiao, Andrea Tazbirkova, Jian Ruan, Zhenyang Liu, Zimin Liu, Zhihua Li, Lili Sheng, Yanru Qin, Jieer Ying, Xianjun Yu, Jian Zhang, Yiping Mou, Chuangxin Lu, Ping Chen, Suyi Li, Jie Li, Xiujuan Qu, Ting Deng, Juan Du, Aiping Zhou, Enxiao Li, Xianglin Yuan, Xinjun Liang, Weiming Yu, Michelle Morris, Yang Luo, Xin Zhao, Yingmei Guo, Hui Zhou, Lin Shen
More posts featuring pancreatic cancer treatment on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023